魯抗醫藥(600789.SH)連續8個漲停提示風險 當前市盈率明顯高於行業平均水平
格隆匯2月6日丨魯抗醫藥(600789.SH)公佈,鑑於近期公司股票波動較大,現對公司有關事項和風險説明如下,敬請廣大投資者理性投資,注意投資風險。
一、公司當前市盈率明顯高於行業平均水平
根據中證指數有限公司發佈的中證行業分類結果顯示:截至2020年2月6日,公司所處“化學藥”行業的靜態市盈率為44.32,滾動市盈率為42.65;公司的靜態市盈率為90.98,滾動市盈率為123.37。公司當前的靜態市盈率、滾動市盈率均明顯高於同行業的平均水平。
二、公司產品結構、主營業務未發生重大變化
公司所從事的主要業務包括醫藥產品的研發、生產和銷售。公司產品主要涉及人用抗生素、獸用農用抗生素、心血管類及降糖類藥物等。目前產品結構和主營業務均未發生重大變化。
三、公司2019年前三季度扣非淨利潤下滑
2019年1-9月,歸屬於上市公司股東的淨利潤1.02億元,同比下降29.42%;歸屬於上市公司股東的扣除非經常性損益的淨利潤6632.86萬元,同比下降45.08%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.